MacroGenics (MGNX) to Release Quarterly Earnings on Thursday

MacroGenics (NASDAQ:MGNX) is anticipated to release its earnings data after the market closes on Thursday, March 20th. Analysts expect MacroGenics to post earnings of ($0.23) per share and revenue of $34.17 million for the quarter. Investors that wish to register for the company’s conference call can do so using this link.

MacroGenics Stock Up 3.9 %

MGNX opened at $2.38 on Thursday. MacroGenics has a fifty-two week low of $2.15 and a fifty-two week high of $19.54. The firm has a market cap of $149.38 million, a PE ratio of -1.51 and a beta of 2.12. The business has a fifty day simple moving average of $2.83 and a 200-day simple moving average of $3.28.

About MacroGenics

MacroGenics, Inc, a biopharmaceutical company, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens.